Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: ABBV-706 faces off against standard care

NCT ID NCT07365241

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 16 times

Summary

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to shrink tumors and help people live longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 531 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed Relapsed/Refractory (R/R) Small Cell Lung Cancer (SCLC). * Participants must have progressed on prior systemic therapy, with CPI (if eligible) and prior tarlatamab, defined as: * In the 1L and 2L setting respectively, platinum-based chemotherapy (i.e., carboplatin or cisplatin and etoposide with CPI, if eligible for CPI) and 2L tarlatamab; or * In the 1L and 2L setting, platinum-based chemotherapy (i.e., carboplatin and etoposide with atezolizumab and lurbinectedin in combination with atezolizumab maintenance and 2L tarlatamab; or * In the 1L setting, platinum-based chemotherapy (i.e., carboplatin or cisplatin and etoposide with CPI if eligible) in combination with tarlatamab in frontline induction and/or maintenance * Participants must be considered suitable to receive SOC comparator (topotecan, lurbinectedin, or amrubicin). * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment. * Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Participants with brain metastasis from an extracranial solid tumor are eligible if the brain metastases are: * Previously treated and not requiring anticonvulsants and steroids for at least 7 days prior to first dose of study treatment. If required for management, subjects on a steroid equivalent of prednisone dose of ≤ 10 mg/day are eligible or; * Untreated and asymptomatic not requiring anticonvulsants and steroids for at least 7 days prior to the first dose of study treatment. If required for management, subjects on a steroid equivalent of prednisone of ≤ 10 mg/day are eligible. Exclusion Criteria: * Participants with known active/symptomatic central nervous system metastases. * Participants with a history of interstitial lung disease (ILD) or pneumonitis that previously required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan. * Participants with any clinically significant conditions that would adversely affect the participation in the study, and the subject should have a life expectancy of at least 3 months. * Participants who have received prior treatment with a seizure-related 6 homolog (SEZ6) targeted Antibody drug conjugate (ADC), other targeted ADCs, or any other investigational agent not including tarlatamab in 1L. * Participants who have received prior treatment with any Top1i such as topotecan, irinotecan, belotecan, camptothecin, rubitecan, exatecan or locally approved topoisomerase I inhibitor (Top1i) payload.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    61 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 280600

    RECRUITING

    Marseille, Bouches-du-Rhone, 13915, France

  • Baptist Memorial Hospital /ID# 281405

    RECRUITING

    Memphis, Tennessee, 38120, United States

  • Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063

    RECRUITING

    Birmingham, Alabama, 35243, United States

  • Blue Ridge Cancer Care - Blacksburg /ID# 281583

    RECRUITING

    Blacksburg, Virginia, 24060, United States

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Centre Hospitalier Universitaire Vaudois /ID# 280847

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

  • City Of Hope - Atlanta /ID# 279929

    RECRUITING

    Newnan, Georgia, 30265, United States

  • City Of Hope - Chicago /ID# 281335

    RECRUITING

    Zion, Illinois, 60099, United States

  • City Of Hope - Phoenix /ID# 281323

    RECRUITING

    Goodyear, Arizona, 85338, United States

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396

    RECRUITING

    Irvine, California, 92618, United States

  • City of Hope National Medical Center /ID# 281322

    RECRUITING

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute /ID# 279690

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • EOC Ospedale Regionale Lugano /ID# 280583

    RECRUITING

    Lugano, Canton Ticino, 6900, Switzerland

  • FirstHealth of the Carolinas- Speciality Center /ID# 279857

    RECRUITING

    Pinehurst, North Carolina, 28374, United States

  • Florida Cancer Specialists & Research Institute - South /ID# 281387

    RECRUITING

    Fort Myers, Florida, 33901, United States

  • Franciscan St. Francis Health /ID# 279788

    RECRUITING

    Indianapolis, Indiana, 46237, United States

  • Fujita Health University Hospital /ID# 279969

    RECRUITING

    Toyoake, Aichi-ken, 470-1192, Japan

  • Henry Dunnant Hospital Center /ID# 280369

    RECRUITING

    Athens, Attica, 11526, Greece

  • Hirosaki University Hospital /ID# 279926

    RECRUITING

    Hirosaki, Aomori, 036-8563, Japan

  • Hokkaido Cancer Center /ID# 280024

    RECRUITING

    Sapporo, Hokkaido, 003-0804, Japan

  • Hopitaux Universitaires de Geneve /ID# 280748

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

  • Hospital Clinic de Barcelona /ID# 281271

    RECRUITING

    Barcelona, 08036, Spain

  • Interbalkan Medical Center Of Thessaloniki /ID# 280361

    RECRUITING

    Thessaloniki, 57001, Greece

  • Juntendo University Hospital /ID# 280095

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Kansai Medical University Hospital /ID# 279925

    RECRUITING

    Hirakata-shi, Osaka, 573-1191, Japan

  • Kindai University Hospital /ID# 280034

    RECRUITING

    Sakai-shi, Osaka, 590-0197, Japan

  • Kitasato University Hospital /ID# 280033

    RECRUITING

    Sagamihara-shi, Kanagawa, 252-0375, Japan

  • Klinikum Kassel /ID# 280427

    RECRUITING

    Kassel, Hesse, 34125, Germany

  • Kobe University Hospital /ID# 280290

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Kyushu University Hospital /ID# 279964

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Metropolitan Hospital /ID# 280359

    RECRUITING

    Piraeus, Attica, 18547, Greece

  • Minnesota Oncology - Edina Clinic /ID# 280698

    RECRUITING

    Edina, Minnesota, 55435, United States

  • Moffitt Cancer Center /ID# 279732

    RECRUITING

    Tampa, Florida, 33612, United States

  • Niigata University Medical and Dental Hospital /ID# 280027

    RECRUITING

    Niigata, Niigata, 951-8520, Japan

  • Nippon Medical School Hospital /ID# 280687

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • OSF St. Francis Medical Center /ID# 279930

    RECRUITING

    Peoria, Illinois, 61637-0001, United States

  • Okayama University Hospital /ID# 280023

    RECRUITING

    Okayama, Okayama-ken, 700-8558, Japan

  • Oncology Hematology Care - Fairfield /ID# 280641

    RECRUITING

    Fairfield, Ohio, 45014, United States

  • Ordensklinikum Linz Elisabethinen /ID# 281314

    RECRUITING

    Linz, Upper Austria, 4010, Austria

  • Orlando Health Cancer Institute /ID# 280418

    RECRUITING

    Orlando, Florida, 32806, United States

  • Osaka International Cancer Institute /ID# 280026

    RECRUITING

    Osaka, Osaka, 5418567, Japan

  • SCRI Oncology Partners /ID# 279779

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Saitama Medical University International Medical Center /ID# 279962

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Sendai Kousei Hospital /ID# 279790

    RECRUITING

    Sendai, Miyagi, 981-0914, Japan

  • Shenandoah Oncology /ID# 280699

    RECRUITING

    Winchester, Virginia, 22601, United States

  • Shizuoka Cancer Center /ID# 279924

    RECRUITING

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Springfield Clinic - First /ID# 281309

    RECRUITING

    Springfield, Illinois, 62702, United States

  • St. Lukes University Hospital /ID# 280204

    RECRUITING

    Bethlehem, Pennsylvania, 18015, United States

  • Teikyo University Hospital /ID# 280307

    RECRUITING

    Tokyo, 173-8605, Japan

  • Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619

    RECRUITING

    Knoxville, Tennessee, 37909, United States

  • Texas Oncology - Northeast Texas /ID# 280642

    RECRUITING

    Tyler, Texas, 75702, United States

  • The University of Texas MD Anderson Cancer Center /ID# 280070

    RECRUITING

    Houston, Texas, 77030, United States

  • Universitaetsklinikum Koeln /ID# 280867

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University Hospital Basel /ID# 280787

    RECRUITING

    Basel Town, Canton of Basel-City, 4031, Switzerland

  • University Of Tennessee Medical Center /ID# 279896

    RECRUITING

    Knoxville, Tennessee, 37920, United States

  • University of Wisconsin /ID# 279909

    RECRUITING

    Madison, Wisconsin, 53792-0001, United States

  • Usa Mitchell Cancer Institute /ID# 280198

    RECRUITING

    Mobile, Alabama, 36604, United States

  • Vanderbilt University Medical Center /ID# 280169

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Virginia Cancer Specialists - Fairfax /ID# 280710

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • West Virginia University Hospitals /ID# 279883

    RECRUITING

    Morgantown, West Virginia, 26506, United States

  • Willamette Valley Cancer Institute and Research Center /ID# 280617

    RECRUITING

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.